Canada Pension Plan Investment Board Buys 51,400 Shares of Horizon Pharma PLC (HZNP)

Canada Pension Plan Investment Board boosted its stake in shares of Horizon Pharma PLC (NASDAQ:HZNP) by 11.7% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 489,000 shares of the biopharmaceutical company’s stock after buying an additional 51,400 shares during the quarter. Canada Pension Plan Investment Board’s holdings in Horizon Pharma were worth $9,575,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. United Services Automobile Association increased its stake in Horizon Pharma by 11.0% in the second quarter. United Services Automobile Association now owns 27,036 shares of the biopharmaceutical company’s stock worth $448,000 after purchasing an additional 2,679 shares during the period. Globeflex Capital L P increased its stake in Horizon Pharma by 2.5% in the third quarter. Globeflex Capital L P now owns 124,659 shares of the biopharmaceutical company’s stock worth $2,441,000 after purchasing an additional 3,000 shares during the period. Swiss National Bank increased its stake in Horizon Pharma by 1.2% in the third quarter. Swiss National Bank now owns 287,856 shares of the biopharmaceutical company’s stock worth $5,636,000 after purchasing an additional 3,400 shares during the period. SG Americas Securities LLC increased its stake in Horizon Pharma by 25.9% in the second quarter. SG Americas Securities LLC now owns 16,821 shares of the biopharmaceutical company’s stock worth $279,000 after purchasing an additional 3,463 shares during the period. Finally, Rhumbline Advisers increased its stake in Horizon Pharma by 2.2% in the second quarter. Rhumbline Advisers now owns 185,346 shares of the biopharmaceutical company’s stock worth $3,069,000 after purchasing an additional 3,941 shares during the period. Institutional investors own 89.27% of the company’s stock.

In other news, Chairman Timothy P. Walbert sold 408,347 shares of the stock in a transaction on Wednesday, November 14th. The stock was sold at an average price of $21.54, for a total transaction of $8,795,794.38. Following the transaction, the chairman now owns 650,404 shares of the company’s stock, valued at approximately $14,009,702.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 3.90% of the stock is currently owned by corporate insiders.

HZNP opened at $20.06 on Friday. Horizon Pharma PLC has a 12-month low of $12.55 and a 12-month high of $23.38. The company has a debt-to-equity ratio of 2.06, a quick ratio of 1.86 and a current ratio of 1.94. The firm has a market cap of $3.39 billion, a PE ratio of 17.00, a PEG ratio of 1.34 and a beta of 1.02.

Horizon Pharma (NASDAQ:HZNP) last posted its quarterly earnings results on Wednesday, November 7th. The biopharmaceutical company reported $0.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.50 by $0.15. Horizon Pharma had a positive return on equity of 27.14% and a negative net margin of 18.70%. The business had revenue of $325.30 million for the quarter, compared to the consensus estimate of $311.84 million. During the same quarter in the prior year, the company earned $0.26 EPS. The business’s revenue was up 19.8% compared to the same quarter last year. On average, equities analysts expect that Horizon Pharma PLC will post 1.3 EPS for the current year.

HZNP has been the topic of a number of recent analyst reports. Morgan Stanley increased their target price on Horizon Pharma from $16.00 to $24.00 and gave the stock an “equal weight” rating in a research note on Friday, August 17th. Goldman Sachs Group set a $26.00 target price on Horizon Pharma and gave the stock a “buy” rating in a research note on Thursday, October 4th. Stifel Nicolaus increased their target price on Horizon Pharma from $25.00 to $35.00 and gave the stock a “buy” rating in a research note on Thursday, November 1st. BidaskClub lowered Horizon Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, September 26th. Finally, Piper Jaffray Companies set a $25.00 target price on Horizon Pharma and gave the stock a “buy” rating in a research note on Monday, September 24th. Six equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Horizon Pharma currently has an average rating of “Buy” and a consensus price target of $23.25.

ILLEGAL ACTIVITY NOTICE: This piece was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another publication, it was copied illegally and republished in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/12/07/canada-pension-plan-investment-board-buys-51400-shares-of-horizon-pharma-plc-hznp.html.

Horizon Pharma Profile

Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients.

Further Reading: Risk Tolerance

Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Pharma PLC (NASDAQ:HZNP).

Institutional Ownership by Quarter for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply